Vir Biotechnology (VIR) Stock
Biotech company developing immunology treatments for infectious diseases. Here's the price, business snapshot, and what's worth knowing about Vir Biotechnology in October 2026.
Vir Biotechnology, Inc. (VIR) is a small-cap biotechnology company focused on developing immunology-based therapies for infectious diseases. With a market capitalisation around $871.01M, the company is largely clinical-stage and derives value from its pipeline, research partnerships and potential licensing or product revenues if trials succeed. Investors should know Vir’s prospects depend heavily on clinical trial results, regulatory decisions and collaborations with larger partners; these events can create sharp share-price moves in either direction. The stock tends to be volatile and may have limited near-term revenue visibility until late-stage data or approvals. Strengths can include specialised scientific expertise and strategic alliances, while risks include trial failures, funding needs and competitive entrants. This summary is general educational information only and not personalised financial advice. Before investing, consider your objectives, risk tolerance and seek independent financial or tax guidance if needed.
Vir Biotechnology (VIR) Stock Forecast
Analyst price target, next 12 months
$26.56
+137.8% vs today's $11.17
Price range over the last 12 months
Close to its 12-month high
Analysts covering Vir Biotechnology have a consensus 12-month target of $26.56, above the current price of $11.17.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VIR Biotechnology's stock, with a target price indicating significant potential growth.
Financial Health
VIR Biotechnology is strong financially, showcasing impressive revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can materially move the stock, though outcomes are uncertain and can swing valuation.
Partnership Impact
Collaborations and licensing deals can de‑risk programmes and provide funding, but commercial success is not guaranteed.
Volatile Small Cap
As a small-cap clinical company, shares can be volatile; consider time horizon and risk tolerance before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
